Free Trial
NASDAQ:MGX

Metagenomi Q2 2026 Earnings Results & Report

Metagenomi logo
$0.82 +0.12 (+17.14%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Metagenomi missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.73 versus the -$0.5531 consensus estimate, while revenue of -$257 thousand fell short of the $3.01 million estimate by $3.27 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Metagenomi EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.5531
Beat/Miss
Missed by -$0.1769
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Metagenomi Revenue Results

Actual Revenue
-$257 thousand
Expected Revenue
$3.01 million
Beat/Miss
Missed by -$3.27 million
YoY Revenue Growth
N/A

Metagenomi Q2 2026 Earnings FAQ

Metagenomi (NASDAQ:MGX) reported earnings of -$0.73 per share for Q2 2026, missing the consensus estimate of -$0.5531. The report was announced on Monday, August 10, 2026.

Metagenomi reported revenue of -$257 thousand for Q2 2026, against a consensus estimate of $3.01 million.

Metagenomi Earnings Headlines

Metagenomi Gets Investigational Approval for Hemophilia Treatment
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Metagenomi Therapeutics: Q3 earnings snapshot
Metagenomi (MGX) Expected to Post Earnings on Tuesday
See More Metagenomi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email.

About Metagenomi

Metagenomi (NASDAQ:MGX) is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools.

Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction. Its research activities have included the discovery of novel nucleases and other genome-editing components, as well as the advancement of potential therapeutic programs in areas such as metabolic and liver-related disorders.

Founded in 2018, Metagenomi is based in Emeryville, California. The company’s work is primarily focused on research and development, with its products and programs intended for potential use in human medicine rather than commercial sale. Metagenomi became a publicly traded company on the Nasdaq under the symbol MGX in 2024.

View Metagenomi Profile